Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
This is a six week, double blind,placebo controlled study for patients with schizophrenia or
schizoaffective disorder treated with an atypical antipsychotic for at least two months.
Subjects will be randomized to take armodafinil (Nuvigil) or placebo along with their current
antipsychotic and tested at baseline and week 6 for differences in memory, attention and
problem-solving ability. Changes in weight during the six week study will also be tracked.
Phase:
Phase 4
Details
Lead Sponsor:
Vanderbilt University Vanderbilt University Medical Center
Collaborators:
Cephalon National Alliance for Research on Schizophrenia and Depression